

Press Conference

### Beyond Patent Cliff, Towards New Growth Stage with Innovative Drugs

December 12, 2012 Yoshihiko Hatanaka President & CEO Astellas Pharma Inc.




#### **Cautionary Statement Regarding Forward-Looking Information**


This material includes forward-looking statements based on assumptions and beliefs in light of the information currently available to management and subject to significant risks and uncertainties.


Actual financial results may differ materially depending on a number of factors including adverse economic conditions, currency exchange rate fluctuations, adverse legislative and regulatory developments, delays in new product launch, pricing and product initiatives of competitors, the inability of the company to market existing and new products effectively, interruptions in production, infringements of the company's intellectual property rights and the adverse outcome of material litigation.

This material contains information on pharmaceuticals (including compounds under development), but this information is not intended to make any representations or advertisements regarding the efficacy or effectiveness of these preparations nor provide medical advice of any kind.










### **Emerging Markets: Sales Growth Under GCL model**



AGS-16M8F/

AGS -16C3F

ASG-5ME

ASG-22ME

Antibody

Renal cancer

Prostate cancer,

Pancreatic cancer

Solid tumors

Antibody utilizing

(Target: ENPP3) Antibody utilizing

(Target: SLC44A4) Antibody utilizing

(Target: Nectin-4)

ADC


ADC


ADC

V

~

1





### **Astellas Growth Strategy**

#### Maintain and expand existing GCL franchises

- Urology: Maximize OAB global sales
- Transplantation: Maximize global Prograf business

#### Develop oncology franchise rapidly as 3<sup>rd</sup> GCL

- Maximize existing product sales and accelerate developments

#### Maximize global sales

- Grow sales of multiple products in each region
- Strengthen business in emerging markets under GCL model

#### Improve R&D productivity

- Reinforce "Precision Medicine" approach
- Promote "Multi-Track R&D" approach

#### Optimize resource allocation




## **Astellas Press Conference**

### Momentum for Global Health ~Pharmaceutical Industry~



December 12<sup>th</sup>, 2012 Representative Director, Chairman of the Board Masafumi Nogimori




# European, US pharmaceutical companies actively engaged in access to health initiatives




Approaches to contribute to access to health	Details
R&D	<ul> <li>Research and development of innovative products and formulations, additional pediatric indications, etc (using Private Development Partnerships)</li> </ul>
Flexible pricing	<ul> <li>Affordable price setting for least developed countries and areas</li> </ul>
Intellectual property (IP)	<ul> <li>Implement the patent system in a flexible manner, considering non-application of IP rights in certain countries and flexibility of associated conditions</li> </ul>
Technology transfer	<ul> <li>Support capacity building, know-how transfer, education/training on product manufacturing and quality control</li> </ul>
Product donations/ Philanthropy	<ul> <li>Donation of products</li> <li>Philanthropic activities to structure healthcare systems</li> </ul>

#### Japanese pharmaceutical companies' contribution $\gg_{astellas}$



Source:

"JPMA's (Japan Pharmaceutical Manufacturers Association) Contribution to Global Health"



### **Astellas Press Conference**


### Access to Health: A New Initiative for NTDs (NTDs: Neglected Tropical Diseases)

Changing tomorrow

astellas

December 12<sup>th</sup>, 2012 Senior Corporate Executive Vice President, External Relations Masaru Imahori astellas

#### **Our contribution to Access to Health**



#### **Access to Health Mission Statement**

Astellas' raison d'être is to contribute toward improving the health of people around the world through the provision of innovative and reliable pharmaceuticals products. Guided by this business philosophy, our main efforts towards "Access to Health" lie in discovering, developing and providing innovative medicines for patients. Astellas also endeavors to advance "Access to Health" by engaging in initiatives in countries where adequate medical care is needed. In order to develop our activities, we will continue to work with and maintain close dialogue with multiple public health stakeholders.

astellas

astellas



20

astellas

We will improve Access to Health by


-utilizing our own strengths and assets (product,

technology, know-how)

-collaborate with optimal partners



- ① Collaborative drug discovery research for anti-protozoan compounds for NTDs
- ② Contribution to development of a pediatric formulation for treatment of schistosomiasis



#### **New initiatives**



- 1. New drug discovery research for anti-protozoan compounds for NTDs
- ⇒Utilizing our know-how and assets in drug discovery research

2. Contribution to development of a pediatric formulation for treatment of schistosomiasis

⇒Utilizing our cutting-edge pharmaceutical technology

#### **New initiatives**



1. New drug discovery research for anti-protozoan compounds for NTDs

⇒Utilizing our know-how and assets in drug discovery research

2. Contribution to development of a pediatric formulation for treatment of schistosomiasis

⇒Utilizing our cutting-edge pharmaceutical technology

#### **Our approach**


#### <u>Feature(1)</u> Select 3 NTDs with highly unmet medical needs (Leishmaniasis, Chagas disease, and Sleeping sickness)


### <u>Feature</u> Open innovation drug discovery approach

#### Overview of NTDs drug discovery collaboration

New drug discovery research for NTDs

In cooperation with 5 research organizations in Japan through a publicprivate partnership, we will take three types of ultramodern approaches relating to new drug discovery





#### **New initiatives**



1. New drug discovery research for anti-protozoan compounds for NTDs

⇒Utilizing our know-how and assets in drug discovery research

2. Contribution to development of a pediatric formulation for treatment of schistosomiasis

⇒Utilizing our cutting-edge pharmaceutical technology

## The current difficulties of treatment of schistosomiasis

Pediatric formulation development for schistosomiasis

28

- Schistosomiasis –one of the most prevalent neglected diseases
- estimated approximately 200 million infected people

astellas

- mostly prevalent in African region
- high prevalence of infection in children

>A clear unmet medical need for a pediatric suitable formulation Current

- standard care with Praziquantel is only available for adults and older children and there is no pediatric formulation that can be used in the very young children age group
- very young children cannot swallow due large tablet size (1050mg, 23x8.5mm)
- strong bitter taste of active ingredients leads to low compliance for patients

Access to Health

MERCK

July 2, 2012

🐽 🗢 🕇 🖬 Pharma

29

**News Release** 

New public-private partnership to develop a treatment for schistosomiasis-infected preschool children

Swiss TPH

#### Astellas' role

- Astellas' contribution by utilizing our innovative pharmaceutical technologies
- Several formulations are under evaluation to consider the following points
  - suitable formulation and size which infants (>3 months) can swallow
  - ✓ reduction of bitter taste
  - ✓ dosage adjustment
  - ✓ stability in hot and humid climates (ex: African region)
  - ✓ manufacturability
  - ✓ speedy development is preferred

#### 30

stellas

#### The value of "Access To Health" initiative

- We endeavor to fulfill our social mission as a pharmaceutical company to contribute to the health of people worldwide
- We believe that the Access to Health initiative brings a synergistic effect on our business activities from a long-term perspective, such as establishing a new drug discovery model through partnerships with academia, as well as strengthening our relationships with various stakeholders involved in global health and building relationships with government and local partners in developing countries.





Astellas will continue our challenge to solve global health issues through our Access to Health initiatives

